Boston Biomedical halts phase III pancreatic cancer trial testing napabucasin July 3, 2019 By Lee Landenberger No Comments Boston Biomedical Inc. shuttered phase III study Canstem111P of napabucasin for patients with metastatic pancreatic ductal adenocarcinoma, adding to the list of studies that have fallen in pancreatic cancer.Read More